The Future Impact of Proximity Ligation Assays in Cancer Diagnostics Through Senstive And Multiplexed Protein-based Biomarker Assays in Plasma and Tissue Samples
Simon Fredriksson, Chief Scientific Officer, Olink
Date Posted: Tuesday, March 02, 2010
Launch presentation
About the speaker
Dr. Fredriksson is the Chief Scientific Officer at Olink Bioscience (Uppsala, Sweden) and has been a key figure in inventing and developing the proximity ligation assay for protein detection. After obtaining his PhD in molecular medicine in 2002 at Uppsala University he spent four years at Stanford University implementing PLA into a senstivite high throughput cancer biomarker research tool. He is a co-founder and board member of Olink Bioscience focused on the commercialization of in situ and in vitro PLA technology.
Abstract
Methods consuming small sample amounts and allow for sensitive screening of large numbers of putative biomarkers indicative of disease are required to advance biomarker discovery and validation. We present multiplex proximity ligation assays (PLA) were protein analytes are converted to unique DNA amplicons and subsequently detected by high throughput quantitative PCR. These multiplexed profiling panels solve many analytical problems found in biomarker verification, such as sensitivity (low femto Molar), multiplexing, throughput, and sample consumption (one micro Litre of plasma). As the assay can use either matched monoclonal antibody pairs or even single batches of polyclonal antibodies both with high detection specificity, a wider range of potential biomarkers can be targeted compared to conventional immunoassay methods. In another incarnation of PLA performed in situ, the assay can precisely quantify proteins and protein interactions in FFPE tissue providing localized data through subjective single molecule counting and fluorescence microscopy. The ability to quantify protein modifications and protein-protein interactions in situ using pairs of primary target specific antibodies opens a new realm of interaction based biomarker opportunities.
Launch presentation